134044-50-1

Basic information

• Product Name: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE
• Synonyms: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE;imidazo[1,2-a]pyrimidine, 2-(3-nitrophenyl)-;2-(3-Nitro-phenyl)-imidazo[1,2-a] pyrimidine, >96%
• CAS NO: 134044-50-1
• Molecular Formula: C₁₂H₈N₄O₂
• Molecular Weight: 240.22
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 134044-50-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.448 g/cm³
• Refractive Index: 1.726
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(134044-50-1)
• EPA Substance Registry System: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(134044-50-1)

Safety Data

• Hazardous Substances Data: 134044-50-1(Hazardous Substances Data)

Usage

General Description

2-(3-Nitro-phenyl)-imidazo[1,2-a]pyrimidine is a chemical compound with a molecular formula C12H8N4O2. It is a heterocyclic aromatic compound consisting of an imidazole and pyrimidine ring fused together. 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE is known for its potential use in various pharmaceutical applications, including as a building block in the synthesis of biologically active molecules. The presence of a nitro group in the phenyl ring makes this compound useful for its potential as a drug candidate. It has also been studied for its possible antiviral and anticancer activities. However, further research and studies are needed to fully understand and harness the potential of this chemical compound.

InChI:InChI=1/C12H8N4O2/c17-16(18)10-4-1-3-9(7-10)11-8-15-6-2-5-13-12(15)14-11/h1-8H

Upstream product

• 121-89-1 3-Nitroacetophenone 
• 109-12-6 2-aminopyrimidine 
• 92554-40-0 α-tosyloxy-m-nitroacetophenone 
• 2227-64-7 3'-nitro-2-bromoacetophenone 

Downstream Products

• 439108-84-6 3-(imidazo[1,2-a]pyrimidin-2-yl)aniline 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists

In this study, a series of fused-heterocyclic derivatives were systematically designed and synthesized using an efficient route, and evaluated in terms of GLP-1R agonist activity. We employed short synthetic steps and reactions that are tolerant of the presence of various functional groups and suitable for parallel operations to enable the rapid generation of libraries of diverse and structurally complex small molecules. Of the compounds synthesized, 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a] pyridin-2-yl)phenyl methanesulfonate (8e) was the most potent agonist with an EC50 of 7.89 μM, and thus is the compound with the greatest potential for application. These findings represent a valuable starting point for the design and discovery of small-molecule GLP-1R agonists that can be administered orally.

A facile [hydroxy(tosyloxy)iodo]benzene mediated synthesis of 2-arylimidazo[1,2-a]pyrimidines and their conversion into 3-bromo-2- arylimidazo[1,2-a]pyrimidines

α-Tosyloxyketone 2, obtained through hypervalent iodine oxidation of enolizable ketones using [hydroxy(tosyloxy)iodo]benzene (HTIB) in acetonitrile, on treatment with 2-aminopyrimidine 3 generates regioselectively 2-arylimidazo[1,2-a]pyrimidine 6 which up